Articles tagged "Rejection"

2019 American Transplant Congress
Subclinical Antibody Mediation Rejection in Stable Kidney Recipients with De Novo Donor Specific Antibodies and Correlation with Donor Derived Cell Free DNA Testing
A. P. Bregman, E. J. Stites, J. Gralla, A. Wiseman, J. E. Cooper
Kidney and Pancreas Transplant, University of Colorado-Denver, Aurora, CO
*Purpose: Subclinical antibody mediated rejection (sAMR) is associated with inferior graft outcomes but its diagnosis relies on the presence of biomarkers as well as histology.…
2019 American Transplant Congress
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant
P. W. Baron¹, J. Weissman², F. Fazeli³, C. Zuppan⁴, R. Villicana³, P. Wai¹, L. Beeson⁵, M. De Vera¹
¹Surgery/Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ²Pharmacy, Loma Linda University Health, Loma Linda, CA, ³Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ⁴Pathology, Loma Linda University Health, Loma Linda, CA, ⁵Center for Nutrition, Healthy Lifestyle and Disease Prevention/School of Public Health, Loma Linda University Health, Loma Linda, CA
*Purpose: Rabbit anti-thymocyte globulin (rATG) cumulative dose needed to effectively and safely prevent acute cellular rejection is unknown. This study compares the efficacy of total…
2019 American Transplant Congress
Urinary Microtubule-Associated Protein Light Chain3 and Neutrophil Gelatinase-Associated Lipocalin, as Potential Noninvasive Biomarkers for Subclinical Rejection at 3 Months after Kidney Transplantation
S. Tajima¹, R. Fu², M. Fukuda², K. Suetsugu², Y. Okabe³, S. Masuda¹
¹Pharmacy, Kyushu University Hospital, Fukuoka, Japan, ²Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, ³Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
*Purpose: Biopsy proven acute rejection without clinical symptoms such as subclinical rejection (SCR) is supposed to associate graft loss in the long term post kidney…
2019 American Transplant Congress
Racial Disparities in Documentation of Non-Adherence and Its Relation to Rejection in Pediatric Kidney Transplant Recipients
T. Melanson, J. Hogan, K. Maroney, R. Patzer, R. George
Emory University, Atlanta, GA
*Purpose: Black patients have historically been disadvantaged throughout the transplant process. Many factors impact the success of kidney transplantation, but the need for strict adherence…
2019 American Transplant Congress
Is Pre-transplant Plasmapheresis For Patients With Insignificant Abo Blood Type Antibody In Abo Blood Type Incompatible Kidney Transplant Necessary? – A Japanese Single Center Study.
M. Miyazaki, A. Mitsuke, H. Higuchi, N. Fukuzawa, H. Tanaka, T. Hirano, T. Seki, H. Harada
Urology and Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan
*Purpose: ABO incompatible kidney donor (ABOiKT) is still precious to fill up the extremely organ donor shortages in our country. Though plasmaphresis (PP) as desensitization…
2019 American Transplant Congress
Karnofsky Performance Score as a Predictor of Acute Cellular Rejection Post Liver Transplantation
N. Kapila¹, K. Al Khalloufi², F. Salomon³, K. Kapila⁴, A. Gupta³, X. B. Zervos²
¹Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, ²Transplant, Cleveland Clinic Florida, Weston, FL, ³Internal Medicine, Cleveland Clinic Florida, Weston, FL, ⁴Internal Medicine, University of Miami/JFK Medical Center, Atlantis, FL
*Purpose: The incidence of acute cellular rejection (ACR) following liver transplantation (LT) ranges from 20-40%. Development of ACR is associated with increased risk of graft…
2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…
2019 American Transplant Congress
Impact of Early Borderline Histological Changes on Subsequent Events in Renal Transplant Recipients
R. Mehta, S. Tandukar, D. Jorgensen, I. Owoyemi, N. Shah, C. Puttarajappa, C. Wu, S. Hariharan
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: The significance of borderline changes suspicious for rejection noted on early renal allograft biopsies on subsequent events in renal transplant recipients is unclear.*Methods: Between…
2019 American Transplant Congress
Basiliximab versus T-cell Depleting Induction Therapy in Elderly Kidney Transplant Recipients
G. Vranic, H. Shah, B. Thomas, B. Javaid, J. Moore, M. Cooper, A. Gilbert
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: The ideal induction therapy for elderly kidney transplant recipients is not known. Given concerns about increased risk of infection and malignancy and perceived decreased…